![]() For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience's business in general, see the risk factors and other risks set forth in Twist Bioscience's Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on Novemand subsequent filings with the SEC. Such risks and uncertainties include, among others, the risks and uncertainties of the duration, extent and impact of the COVID-19 pandemic, including any reductions in demand for our products (or deferred or canceled orders) globally or in certain regions the ability to attract new customers and retain and grow sales from existing customers risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive the retention of employees of acquired companies and the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits supply chain and other disruptions caused by the COVID-19 pandemic or otherwise risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience's patents or proprietary rights and the risk that Twist Bioscience's proprietary rights may be insufficient to protect its technologies. ![]() Such forward- looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. All statements other than statements of historical facts contained herein are forward- looking statements reflecting the current beliefs and expectations of management and include statements regarding, among other things, future financial performance, expectations and objectives of management, market opportunity and growth, anticipated growth of business lines and the timing for such growth, the development and commercialization of Twist Bioscience's data storage business. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.This presentation contains forward-looking statements. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. ![]() The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. A replay of the presentation will be archived for a period of 30 days following the conclusion of the live event. The presentation will be webcast live and can be accessed by visiting the "Investor Calendar" page of the investor relations section of the company's website here. Leproust, Ph.D., CEO and co-founder of Twist Bioscience will present at the Baird 2022 Global Healthcare Conference on Tuesday, September 13th, at 2:35 p.m. SOUTH SAN FRANCISCO, Calif., September 06, 2022-( BUSINESS WIRE)-Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |